New Podcast Examines Global Health Workforce Development and Health Worker Mobility
"Care Anywhere" from CGFNS International now available on major podcast streaming sites
PHILADELPHIA, PA / ACCESSWIRE / November 12, 2024 / CGFNS International, a worldwide leader in international credentials evaluation and certification to support health worker careers, has launched a podcast exploring health workforce challenges that are now at the very center of the global healthcare landscape.
Care Anywhere - The Global Health Workforce Podcast
Watch & Subscribe at cgfns.org/podcast
Care Anywhere: The Global Health Workforce Podcast includes discussions with thought leaders and innovators who are tackling these issues, as well as the voices of health workers around the world who face these challenges every day of their lives. Topics revolve around practice evolution, workforce shortages, and the growing global demand for healthcare talent.
Listeners and viewers can subscribe now through their favorite podcast streaming sites including Apple Podcast, Spotify, and YouTube, as well as via the CGFNS website, where a new episode will drop every two weeks.
Four episodes of Care Anywhere are available now. In the most recent one, ICN: Investing in the Future of the Global Nurse Workforce, guest Howard Catton, CEO of the International Council of Nurses, provides his perspectives on addressing the projected global shortage of 13 million nurses at the end of this decade.
Other available episodes include:
Raising all Boats: Building Capacity for Global Health. Mary Sebert, Director of Global Nursing at Massachusetts General Hospital's Center for Global Health, is interviewed on the challenges and opportunities facing the global health workforce, focusing on how capacity building and education are essential in addressing workforce shortages.
The Next Frontier in Nursing: Embracing Tech & AI. Two leading figures in nursing informatics, Kathleen McGrow, Chief Nursing Informatics Officer (CNIO) at Microsoft, and Romina Elias, CNIO at Dell Technologies, explore how technology is transforming the future of nursing and healthcare.
Care Anywhere: The Journey Begins. The inaugural episode features Dr. Peter Preziosi, President and CEO of CGFNS International, Inc., and Julia To Dutka, Chief of the CGFNS Global Health Workforce Development Institute, who explore the evolving landscape of healthcare, workforce shortages, and the need for innovation in credentialing and workforce development.
In the coming months, Care Anywhere will also feature working nurses and other healthcare professionals describing their experiences and the challenges they face in their career mobility journeys. Subjects will include their pathways to education and credentialing, their career advancement decisions, and what they are doing today to lead care model evolution within their health systems.
"Understanding and addressing global health workforce challenges is increasingly important to advancing the health workers and health systems worldwide. We see this podcast series catalyzing global opportunities with people and organizations interested in improving population health, health equity, and health access as we explore the workforce in the context of care model evolution," said Preziosi.
Care Anywhere is hosted by Lea Sims, CGFNS Chief Marketing and Communications Officer. Sims has 30 years in health information management, health IT, and healthcare communications. She is the former global healthcare practice leader for Verizon Enterprise and founding host of Verizon's Healthcare on Air podcast.
"I'm looking forward to great conversations with nurses, educators, regulators, and others who are thoughtfully focused on solving workforce development challenges in healthcare," said Sims. "We're at a powerful intersection where global shortages are critical and there are big problems to solve, but there has also never been a more exciting time to be a nurse or healthcare worker. New technologies, shifting practice roles, and the opportunity to lead care evolution across global health systems-we're going to dive into all of those industry drivers."
About CGFNS International, Inc.
Founded in 1977 and based in Philadelphia, CGFNS International is an immigration-neutral not-for-profit organization proudly serving as the world's largest credentials evaluation organization for the nursing and allied health professions. CGFNS International is an NGO in Consultative Status with the United Nations Economic and Social Council (ECOSOC) and is a member of the Conference of NGOs in Consultative Relationship with the United Nations (CoNGO).
Contact Information
David St. John
dstjohn@cgfns.org
SOURCE: CGFNS International
View the original press release on newswire.com.
CGFNS International
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections10.12.2024 07:30:00 CET | Press release
Collaboration between Bascom Palmer Eye Institute and Provectus Biopharmaceuticals KNOXVILLE, TN / ACCESSWIRE / December 10, 2024 / VisiRose, a clinical-stage biotechnology company, is introducing Rose Bengal Photodynamic Antimicrobial Therapy (RB PDAT), a groundbreaking, non-invasive investigational treatment for infectious keratitis and other serious eye infections developed by the University of Miami Miller School of Medicine's Bascom Palmer Eye Institute (BPEI). VisiRose, a newly launched company of Provectus Biopharmaceuticals (OTCQB:PVCT) and the University, is focused on commercializing this innovative ocular research by combining a formulation of Provectus's pharmaceutical-grade bioactive synthetic small molecule Rose Bengal Sodium (RBS) and BPEI's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites. RB PDAT offers a potential solution to the growing global problem of antimicrobial resistance (AMR), providing a broad-spectrum ocular thera
Young Girl Discovers a 3,500-year-old Egyptian Amulet9.12.2024 07:40:00 CET | Press release
During a family trip near an archaeological site in Hod Hasharon, 12-year-old Dafna Filshteiner found an ancient scarab. LONDON, UK / ACCESSWIRE / December 9, 2024 / Dafna Filshteiner, age 12, was recently hiking below the ancient site of Tel Qana in Hod Hasharon, when suddenly, to her surprise, she discovered an unusual find a beetle-like stone used as an Egyptian amulet about 3,500 years ago. "I was looking down at the ground to find porcupine needles and smooth pebbles," she says. "And suddenly I picked up an interesting stone. I showed it to my mother, and she said it was just an ordinary stone or a bead. But then I saw a decoration and stubbornly insisted it was more than that, so we searched on the Internet. There, we identified more photos of stones similar to what we had found. We realized that it was something special and immediately called the Antiquities Authority." The family turned to Mor Wiesel, an archaeologist at the Israel Antiquities Authority, who thanked Dafna and h
Loar Announces Launch of Public Offering9.12.2024 06:30:00 CET | Press release
WHITE PLAINS, NY / ACCESSWIRE / December 9, 2024 / Loar Holdings Inc. (NYSE:LOAR) ("Loar") announced today that it has launched the roadshow for the public offering of 4,750,000 shares of its common stock, including 1,583,333 shares offered by certain stockholders and 3,166,667 shares offered by Loar. In addition, such selling stockholders expect to grant the underwriters a 30-day option to purchase up to 712,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions. Loar intends to use the net proceeds from this offering for repayment of borrowings outstanding under its credit agreement and, to the extent of any remaining proceeds, for general corporate purposes, including working capital. Loar will not receive any of the proceeds from the sale of common stock offered by the selling stockholders, including any common stock sold pursuant to any exercise by the underwriters of their option to purchase additional shares. Jefferies and
BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment9.12.2024 03:05:00 CET | Press release
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions. 2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies furth
ProteinQure to Present Data on PQ203, a Novel Peptide-Drug Conjugate for Triple Negative Breast Cancer, at 2024 San Antonio Breast Cancer Symposium6.12.2024 12:30:00 CET | Press release
TORONTO, ON / ACCESSWIRE / December 6, 2024 / ProteinQure, the leading company in computational design of peptide therapeutics, will be presenting compelling new data on the progress of their lead triple negative breast cancer (TNBC) drug PQ203 (December 12, 2024 presentation ID: P4-12-17) at the 2024 San Antonio Breast Cancer Symposium. PQ203 is a novel Peptide Drug Conjugate composed of a Sortilin receptor targeting peptide conjugated to the cytotoxic agent monomethyl auristatin E. The Sortiin receptor is expressed in a high percentage of diseased tissue from TNBC patients and as such represents an innovative treatment for this challenging sub-type of breast cancer. ProteinQure has recently generated data that PQ203 exhibits potent efficacy in a patient-derived xenograft (PDX) model resistant to Sacituzumab Govitecan (Trodelvy™), an antibody drug conjugate that is the emerging standard of care for metastatic TNBC. Additionally, PQ203 has shown an encouraging safety profile. Based on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom